184 related articles for article (PubMed ID: 24887664)
21. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
Gilani SNS; Mehta A; Garcia-Fadrique A; Rowaiye B; Jenei V; Dayal S; Chandrakumaran K; Carr N; Mohamed F; Cecil T; Moran B
Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Su YD; Zhao X; Ma R; Fu YB; Yang ZR; Wu HL; Yu Y; Yang R; Liang XL; Du XM; Chen Y; Li Y
Int J Hyperthermia; 2023; 40(1):2223374. PubMed ID: 37348853
[TBL] [Abstract][Full Text] [Related]
24. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.
Blackham AU; Shen P; Stewart JH; Russell GB; Levine EA
Ann Surg Oncol; 2010 Oct; 17(10):2720-7. PubMed ID: 20422458
[TBL] [Abstract][Full Text] [Related]
26. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
Alexander HR; Bartlett DL; Pingpank JF; Libutti SK; Royal R; Hughes MS; Holtzman M; Hanna N; Turner K; Beresneva T; Zhu Y
Surgery; 2013 Jun; 153(6):779-86. PubMed ID: 23489943
[TBL] [Abstract][Full Text] [Related]
27. Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy.
Sugarbaker PH; Turaga KK; Alexander HR; Deraco M; Hesdorffer M
J Oncol Pract; 2016 Oct; 12(10):928-935. PubMed ID: 27858561
[TBL] [Abstract][Full Text] [Related]
28. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
29. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
30. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
32. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
33. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Chua TC; Quinn LE; Zhao J; Morris DL
J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
[TBL] [Abstract][Full Text] [Related]
35. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
36. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Chua TC; Morris DL; Esquivel J
Ann Surg Oncol; 2010 May; 17(5):1330-6. PubMed ID: 20033321
[TBL] [Abstract][Full Text] [Related]
37. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures.
Passot G; Vaudoyer D; Villeneuve L; Kepenekian V; Beaujard AC; Bakrin N; Cotte E; Gilly FN; Glehen O
J Surg Oncol; 2016 Jun; 113(7):796-803. PubMed ID: 27110915
[TBL] [Abstract][Full Text] [Related]
38. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
39. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
40. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
